Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
1.040
+0.010 (0.97%)
Apr 13, 2026, 10:24 AM EDT - Market open
Biofrontera Employees
As of December 31, 2025, Biofrontera had 94 total employees, including 84 full-time and 10 part-time employees. The number of employees increased by 1 or 1.08% compared to the previous year.
Employees
94
Change (1Y)
1
Growth (1Y)
1.08%
Revenue / Employee
$443,670
Profits / Employee
-$112,085
Market Cap
12.11M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 94 | 1 | 1.08% | 84 | 10 |
| Dec 31, 2024 | 93 | 8 | 9.41% | 92 | 1 |
| Dec 31, 2023 | 85 | 4 | 4.94% | 83 | 2 |
| Dec 31, 2022 | 81 | 12 | 17.39% | 81 | 0 |
| Dec 31, 2021 | 69 | 13 | 23.21% | 69 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| China Pharma Holdings | 215 |
| Rockwell Medical | 157 |
| Aytu BioPharma | 83 |
| Sunshine Biopharma | 52 |
| cbdMD | 42 |
| RedHill Biopharma | 35 |
| BioXcel Therapeutics | 29 |
| Gelteq | 8 |
BFRI News
- 25 days ago - Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 4 weeks ago - Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026 - GlobeNewsWire
- 5 weeks ago - Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris - GlobeNewsWire
- 6 weeks ago - U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be Unpatentable - GlobeNewsWire
- 7 weeks ago - Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities - GlobeNewsWire
- 2 months ago - Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma - GlobeNewsWire
- 2 months ago - Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint - GlobeNewsWire
- 3 months ago - Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth - GlobeNewsWire